Nasdaq

Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Nasdaq

Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 ...
Yahoo Finance

Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely ...
Yahoo Finance

Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood ...
Business Insider

Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for ...
Business Insider

Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational ...
Stockhouse

Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
El confidencial

El negocio de El Rubius en 2020: facturó 2,6M€, ganó 258.000€ y debe 39.000€ a Hacienda

En las cuentas de 2020, Snofokk SL ha reportado una facturación de 2,6 millones de euros, unos gastos de personal de 102.000 euros y unos gastos de explotación de 1,2 millones. Con todo, la empresa ...
CNN

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
COPE

La serie de Rubius volverá en 2020 con una segunda temporada a Movistar+

La serie de animación ambientada en el mundo de los videojuegos y basada en el cómic homónimo del 'youtuber' Rubius, "Virtual Hero", tendrá una segunda temporada de seis episodios, que se estrenarán ...
La Vanguardia

La serie de Rubius volverá en 2020 con una segunda temporada a Movistar+

Madrid, 27 ago (EFE).- La serie de animación ambientada en el mundo de los videojuegos y basada en el cómic homónimo del 'youtuber' Rubius, "Virtual Hero", tendrá una segunda temporada de seis ...